Neal Bhatia, MD

Neal Bhatia, MD, shares his insights on successfully navigating AAD and his session highlights on office politics.

Bhatia also shared insights into ritlecitinib for alopecia areata at Fall Clinical 2023.

As deucravacitinib surpasses its 1-year milestone since approval, clinicians continue to monitor its real-world performance among patients.

In the final part of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.

In part 3 of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.

In part 2 of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.

In part 1 of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the pathogenesis of acne vulgaris, the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.

In the final part of this Frontline Forum series, Neal Bhatia, MD; Dawn Eichenfield, MD, PhD; Lawrence Eichenfield, MD; Linda F. Stein Gold, MD; and Guy Webster, MD, PhD, discuss the practical and clinical considerations in the management of acne vulgaris, reviewing available treatment options and how to treat acne scars.

In part 3 of this Frontline Forum series, Neal Bhatia, MD; Dawn Eichenfield, MD, PhD; Lawrence Eichenfield, MD; Linda F. Stein Gold, MD; and Guy Webster, MD, PhD, discuss the practical and clinical considerations in the management of acne vulgaris, reviewing available treatment options and how to treat acne scars.

In part 2 of this Frontline Forum series, Neal Bhatia, MD; Dawn Eichenfield, MD, PhD; Lawrence Eichenfield, MD; Linda F. Stein Gold, MD; and Guy Webster, MD, PhD, discuss the practical and clinical considerations in the management of acne vulgaris, reviewing available treatment options and how to treat acne scars.

In part 1 of this Frontline Forum series, Neal Bhatia, MD; Dawn Eichenfield, MD, PhD; Lawrence Eichenfield, MD; Linda F. Stein Gold, MD; and Guy Webster, MD, PhD, discuss the practical and clinical considerations in the management of acne vulgaris, reviewing available treatment options and how to treat acne scars.

Neal Bhatia, MD, will guide attendees at Fall Clinical PA & NP on the difference between JAKs and TYKs, as well as the role of PAs and NPs in clinical research.

In part 4 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.

In part 3 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.

In part 2 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.

In part 1 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.

Experts in dermatology discuss their use cases of cemiplimab and reinforce the need for dermatologists to utilize novel and effective treatments within their patient populations.

Dr Aaron Farberg discusses the role of cemiplimab in the management of BCC; highlighting the need to increase the engagement of a multidisciplinary team in the use of this treatment.

Neal Bhatia, MD, and Aaron Farberg, MD, discuss the progression of basal carcinoma and the evolving treatment approaches to this condition.

Experts in dermatology review the dosing and meal requirements need with isotretinoin administration, highlighting the impact and benefit of the novel lidose and micronized formulations.

Linda Stein-Gold, MD and Neal Bhatia, MD discuss their approach to acne management highlighting the novel utility of clascoterone cream 1% and where this fits into their treatment regimens.

In part 5 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

In part 4 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

In part 3 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

In part 2 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

In part 1 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

Drs Raj Chovatiya and Neal Bhatia summarize their final thoughts on the available treatment options for the management of atopic dermatitis.

Raj Chovatiya, M.D., Ph.D. and Neal Bhatia, MD comment on the importance of assessing a treatment’s available clinical trial data, ability to control disease severity, and QoL impacts when assessing atopic dermatitis treatment options.

Experts in dermatology discuss the use of oral and topical JAK inhibitors in clinical practice and their reflection of overarching treatment guidelines and indications.

Drs Raj Chovatiya and Neal Bhatia highlight the biological targets of current and emerging treatments for the management of atopic dermatitis and discuss the importance of safety and long-term data.